These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 15752)

  • 21. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
    Brogden RN; Sorkin EM
    Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
    Azadkhan AK; Truelove SC; Aronson JK
    Br J Clin Pharmacol; 1982 Apr; 13(4):523-8. PubMed ID: 6121576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 24. Evolution of olsalazine.
    Truelove SC
    Scand J Gastroenterol Suppl; 1988; 148():3-6. PubMed ID: 2906475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulphasalazine treatment during breast feeding.
    Järnerot G; Into-Malmberg MB
    Scand J Gastroenterol; 1979; 14(7):869-71. PubMed ID: 44005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.
    Azad Khan AK; Howes DT; Piris J; Truelove SC
    Gut; 1980 Mar; 21(3):232-40. PubMed ID: 6105118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventive effects of sulphasalazine on colorectal carcinogenesis in mice with ulcerative colitis.
    Suzuki S; Sakamoto S; Mitamura T; Sassa S; Kudo H; Yamashita Y
    In Vivo; 2000; 14(3):463-6. PubMed ID: 10904883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.
    van Hees PA; Bakker JH; van Tongeren JH
    Gut; 1980 Jul; 21(7):632-5. PubMed ID: 6107263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation.
    Esbjörner E; Järnerot G; Wranne L
    Acta Paediatr Scand; 1987 Jan; 76(1):137-42. PubMed ID: 2882643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesalazine: a global safety evaluation.
    Brimblecombe R
    Scand J Gastroenterol Suppl; 1990; 172():66. PubMed ID: 1972297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man.
    Fischer C; Maier K; Stumpf E; von Gaisberg U; Klotz U
    Eur J Clin Pharmacol; 1983; 25(4):511-5. PubMed ID: 6140167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.
    Pounder RE; Craven ER; Henthorn JS; Bannatyne JM
    Gut; 1975 Mar; 16(3):181-5. PubMed ID: 235486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Which component of sulphasalazine is active in rheumatoid arthritis?
    Pullar T; Hunter JA; Capell HA
    Br Med J (Clin Res Ed); 1985 May; 290(6481):1535-8. PubMed ID: 2860942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of leucocyte motility by drugs used in ulcerative colitis.
    Rhodes JM; Bartholomew TC; Jewell DP
    Gut; 1981 Aug; 22(8):642-7. PubMed ID: 6116649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An experiment to determine the active therapeutic moiety of sulphasalazine.
    Azad Khan AK; Piris J; Truelove SC
    Lancet; 1977 Oct; 2(8044):892-5. PubMed ID: 72239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sulphasalazine and male infertility: reversibility and possible mechanism.
    Toovey S; Hudson E; Hendry WF; Levi AJ
    Gut; 1981 Jun; 22(6):445-51. PubMed ID: 6114897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
    Rutgeerts P
    Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.
    Azad Khan AK; Nurazzaman M; Truelove SC
    J Med Genet; 1983 Feb; 20(1):30-6. PubMed ID: 6133000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.
    Gibson PR; Jewell DP
    Clin Sci (Lond); 1985 Aug; 69(2):177-84. PubMed ID: 2866061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.